Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Information about the 2019 Novel Coronavirus
RE-MATCH PROTOCOL: PHASE I STUDY OF AUTOLOGOUS TUMOR SPECIFIC LYMPHOCYTE TRANSFER (ALT) plus DC VACCINE (DCV) DURING RECOVERY FROM MYELOABLATIVE CHEMOTHERAPY (MAC) AND AUTOLOGOUS STEM CELL RESCUE (HDC plus ASCR) OR NON-MYELOABLATIVE CHEMOTHERAPY (NMAC) IN PATIENTS WITH RECURRENT CENTRAL PNETS (R-PNET) Gururangan, S., Grant, G., Driscoll, T., Archer, G., Herndon, J., Friedman, H., Kurtzberg, J., Bigner, D., Sampson, J., Mitchell, D. OXFORD UNIV PRESS INC. 2018: 104
View details for Web of Science ID 000438339000345